UK plans world's first artificial blood transfusions by 2017

Image
Press Trust of India London
Last Updated : Jun 28 2015 | 1:22 PM IST
The world's first human trial of artificial blood grown in a lab from stem cells is set to take place in the UK by 2017.
The UK's NHS (National Health Service) Blood and Transplant has announced that manufactured blood will be used in clinical trials with human volunteers within two years.
Research led by scientists at the University of Bristol and NHS Blood and Transplant, used stem cells from adult and umbilical cord blood to create a small volume of manufactured red blood cells.
It is hoped that when the production of this lab-produced blood is successfully scaled up, it will offer an alternative to specialist patients with blood disorders such as sickle cell anaemia and thalassemia who require treatment with regular transfusions and for whom it is difficult to find compatible donors.
The clinical trial of manufactured red blood cells is designed to compare the survival of red cells manufactured from stem cells with that of standard blood donor red blood cells.
This will involve a group of 20 volunteers who will receive a small volume transfusion of between five and ten millilitre of the lab-produced blood.
"Scientists across the globe have been investigating for a number of years how to manufacture red blood cells to offer an alternative to donated blood to treat patients," said Dr Nick Watkins, NHS Blood and Transplant Assistant Director of Research and Development.
"We are confident that by 2017 our team will be ready to carry out the first early phase clinical trials in human volunteers," Watkins said.
"These trials will compare manufactured cells with donated blood. The intention is not to replace blood donation but provide specialist treatment for specific patient groups," he said.
"Research has laid the foundation for current transfusion and transplantation practices. Continued investment in research and development is critical to our role in saving and improving lives through blood and organ donation," he added.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 28 2015 | 1:22 PM IST

Next Story